Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
EA-230
DRUG
3 trials
Sponsors
EBI Anti Sepsis B.V.
, Radboud University Medical Center
Conditions
Coronary Artery Bypass Grafting
Coronary artery disease
Endotoxemia
Systemic Inflammatory Response
Systemic Inflammatory Response Syndrome
Phase 1
PK/PD of EA-230 During Endotoxemia
Completed
NCT02629874
Radboud University Medical Center
Endotoxemia, Systemic Inflammatory Response
Start: 2015-02-28
End: 2015-12-31
Updated: 2016-06-23
Phase 2
Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)
NCT03145220
Radboud University Medical Center
Coronary Artery Bypass Grafting, Systemic Inflammatory Response Syndrome
Start: 2016-06-30
End: 2018-10-31
Updated: 2018-06-26
Phase 3
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospital Stay Following On-Pump Coronary Artery Bypass Grafting Surgery
Not yet recruiting
CTIS2025-525053-39-00
EBI Anti Sepsis B.V.
Coronary artery disease
Target: 150
Updated: 2026-04-29
Related Papers
The Safety, Tolerability, and Effects on the Systemic Inflammatory Response and Renal Function of the Human Chorionic Gonadotropin Hormone-Derivative EA-230 Following On-Pump Cardiac Surgery (The EASI Study): Protocol for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
2019-02-06
10 citations